Incidence, risk factors, and management of alpelisib-associated hyperglycemia in metastatic breast cancer.

ABSTRACT:

Purpose

The combination of fulvestrant with alpelisib, a PI3K inhibitor, improves progression-free survival in metastatic hormone receptor-positive, PIK3CA-mutant breast cancer. This study describes the incidence, risk factors, and treatment of alpelisib-associated hyperglycemia.

Methods

Patients with metastatic breast cancer who received alpelisib from 2013 to 2021 at Memorial Sloan Kettering Cancer Center were included in this retrospective study. Alpelisib prescription dates and patient/tumor characteristics were abstracted from medical records. Risk factors associated with hyperglycemia and alpelisib dose reduction/discontinuation were evaluated using Pearson's χ² tests.

Results

Among 247 patients, baseline median body mass index was 25.4 kg/m²

SUBMITTER: Shen S 

PROVIDER: S-EPMC10863751 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature